In this case, I have a patient with widely metastatic cutaneous melanoma (BRAF wild type, NRAS mutated) who is progressing through pembrolizumab and is being switched to ipilimumab/nivolumab. He has a bulky masseter lesion making it difficult for him to chew. Would you treat with 300cGyx10 or use an alternate hyofractionated regimen?
Correction: the renal cell patient dose was 9 Gy x...